First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

Cholesteryl pullulan (CHP) is a novel antigen delivery system. CHP and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen complexes (CHP-NY-ESO-1) present multiple epitope peptides to the MHC class I and II pathways. Adjuvants are essential for cancer vaccines. MIS416 is a non-toxic mi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Principais autores: Ishihara, Mikiya, Tono, Yasutaka, Miyahara, Yoshihiro, Muraoka, Daisuke, Harada, Naozumi, Kageyama, Shinichi, Sasaki, Takeshi, Hori, Yasuhide, Soga, Norihito, Uchida, Katsunori, Shiraishi, Taizo, Sato, Eiichi, Kanda, Hideki, Mizuno, Toshiro, Webster, Gill A., Ikeda, Hiroaki, Katayama, Naoyuki, Sugimura, Yoshiki, Shiku, Hiroshi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Clinical Trial Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113205/
https://ncbi.nlm.nih.gov/pubmed/31980914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02483-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados